Ọgwụ mgbochi ịba
Expression error: Unexpected < onye ọrụExpression error: Unexpected < onye ọrụExpression error: Unexpected < onye ọrụ
 Malaria vaccine clinical trial poster | |
| Vaccine description | |
|---|---|
| Target disease | Malaria |
| Type | Protein subunit |
| Names | |
| Trade names | Mosquirix |
| Clinical data | |
| Main uses | Prevent malaria[1] |
| Side effects | Fever, irritability, pain at the site of injection[2] |
| Routes of use | RTS,S Intramuscular[2] |
| Typical dose | RTS,S 0.5 ml[2] |
| Legal | |
| Legal status |
|
ọgwụ mgbochi ịba bụ ọgwụ mgbochi a na-agba iji gbochie ọrịa ịba na ọnwụ gbasara ịba.[1] RTS,S (Mosquirix), bụ ọgwụ nke mbụ a kwadoro iji gbochie ịba ma a gbara ya na mba atọ dị na mpaghara Sahara Afrịka .[1] Ọ na-ebelata ihe ize ndụ nke ịba site na 24% ruo 43% n'afọ na-esote mgbe e agbara agba nke atọ ọgwụ a.[2] O dighi abara ndi njem uru.[1] A kwadoro ọgwụ mgbochi ịba nke abụọ, R21 / Matrix-M, na Naịjirịa na Ghana na 2023.[3] ọgwụ mgbochi nke abụọ a rụrụ ọrụ rue ihe dịka 77% .[3] Ọgwụ mgbochi abụọ ndị a kpọọrọ aha chọrọ agba nke anọ ya .[2][3][3]ka ha wee zue.
A na-enye Ọgwụ mgbochi nke Bekee kpọrọ RTS,S ụmụaka dị izu isii ruo ọnwa ọnwa iri na asaa n'akụkụ ụwa ebe Plasmodium falciparum adịghị .[2] Mmetụta maọbụ ihe mgbu ndị ọzọ na- eso ịgba ọgwụ mgbochi a bụ gụnyere ahụ ọkụ, iwe, na ihe mgbu n'ebe a gbara ya bụ ọgwụ.[1] obele ahụ ịda udirii na- emekwa n'ihe dị ka 0.1% na ndị e nyere ọgwụ mgbochi a[1] Enwere nchegbu na ọ bụrụ na a gbaghi agba nke anọ na ọgwụ mgbochi a, ọnwụ banyere ịba nwere ike ịbawanye ọzọ.[1] A na-enye ọgwụ mgbochi ịba nke ndị ahụike kpọrọ R21/Matrix-M na ụmụaka di dị ọnwa ise ruo ọnwa iri atọ na isii .[3]
Ndi Bekee kpọrọ CHMP kwuru okwu ọma banyere RTS,S na afọ 2015 ma kwado ya site na Ahụike mba ụwa (WHO) na 2021. [2] GAVI na-enye $ 160 nde n'etiti 2022 na 2025 maka mwepụta ya bụ ọgwụ mgbochi. [4]R21/Matrix-M ruru ọnụ ego ihe dị ka $US3 otu ọnụ ọgwụ ebe RTS,S ruru ọnụ ego $US6 maka otu ọnu ogwu. [5] R21/Matrix-M bụ ọgwụ mgbochi ọrịa mbụ ruru ebumnuche WHO maka na ọdi ire ihe ruru ala 75% . [6][7] Na 2024 Ndị mba Cameroon bidoro atụmatụ ịmalite inye ụmụaka niile ọgwụ mgbochi a.[8]
Nruaka
dezie- ↑ 1.0 1.1 1.2 Prevatt (2021). "23. Paediatric vaccines for travel outside Europe", in Vesikari: Pediatric Vaccines and Vaccinations: A European Textbook, Second (in en), Switzerland: Springer, 276-279. ISBN 978-3-030-77172-0. Retrieved on 30 January 2022.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Mosquirix: Opinion on medicine for use outside EU. European Medicines Agency (EMA). Archived from the original on 23 November 2019. Retrieved on 22 November 2019.
- ↑ 3.0 3.1 3.2 The country with the highest rate of malaria deaths in the world has approved Oxford's vaccine (en). Quartz (18 April 2023). Archived from the original on 19 April 2023. Retrieved on 19 April 2023.
- ↑ Historic funding to expand roll-out of first-ever malaria vaccine in Africa (en). WHO | Regional Office for Africa. Archived from the original on 22 July 2022. Retrieved on 22 July 2022.
- ↑ "Malaria vaccine big advance against major child killer", BBC News, 2 October 2023. Retrieved on 2 October 2023.
- ↑ Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal. EurekAlert! (23 April 2021). Archived from the original on 27 July 2021. Retrieved on 24 April 2021.
- ↑ Malaria vaccine hailed as potential breakthrough. BBC News (23 April 2021). Archived from the original on 24 April 2021. Retrieved on 24 April 2021.
- ↑ Cameroon starts world's first malaria vaccine program for children (en). CTVNews (23 January 2024). Archived from the original on 23 January 2024. Retrieved on 23 January 2024.